Welcome to our dedicated page for Unitedhealth Gp SEC filings (Ticker: UNH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
UnitedHealth Group Incorporated (UNH) provides extensive disclosure to investors and regulators through its SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents offer a detailed view of the company’s health care and well-being operations, which span UnitedHealthcare’s health benefit programs and Optum’s health services, technology and analytics businesses.
Annual and quarterly reports describe UnitedHealth Group’s consolidated financial condition and results of operations, as well as segment performance for UnitedHealthcare and Optum. They include information on revenues, earnings from operations, medical costs, operating costs, cash flows, capital structure and risk factors. Investors use these filings to understand how trends in medical utilization, Medicare and Medicaid funding, and pharmacy services affect the company’s financial profile.
Current reports on Form 8-K provide timely updates on material events. Recent 8-K filings have covered topics such as quarterly earnings releases, reaffirmation of earnings outlooks, amendments to bylaws to reflect changes in the company’s registered office and registered agent in Delaware, the appointment of new independent directors, and investor presentations. Some 8-K items are furnished under Regulation FD to share information discussed with investors and analysts, including earnings expectations and the impact of acquisitions like Amedisys.
UnitedHealth Group also files 8-Ks to document governance and leadership changes, including the appointment of directors with regulatory and clinical backgrounds. These filings often reference standard indemnification agreements and compensation arrangements for non-employee directors, providing additional transparency into board practices.
On this SEC filings page, users can review UnitedHealth Group’s regulatory disclosures in one place. Real-time updates from EDGAR ensure that new 10-K, 10-Q and 8-K filings, as well as any amendments, appear promptly. AI-powered summaries can help explain complex sections, highlight key metrics, and clarify the implications of items such as changes in outlook, medical cost trends or bylaw amendments. Investors can also monitor executive and director changes reported on Form 8-K and use the filings history to track how UnitedHealth Group’s strategy, capital management and risk profile evolve over time.
UnitedHealth Group Incorporated reported board governance changes focused on oversight of risk and responsibility. The board created a new Public Responsibility Committee to monitor financial, regulatory, and reputational risks, including underwriting and forecasting, regulatory relationships, reputational matters, and mergers and acquisitions. Michele Hooper will chair this committee, with Charles Baker, Timothy Flynn, and Paul Garcia as members.
The company also named F. William McNabb as lead independent director, succeeding Michele Hooper, who remains on the board. In addition, UnitedHealth Group refreshed leadership and membership across its Audit and Finance, Compensation and Human Resources, Governance, and Health and Clinical Practice Policies Committees, assigning specific directors as chairs and members to each.
UnitedHealth Group Incorporated filed an S-8 registration related to employee benefit plans that incorporates prior SEC reports and exhibits by reference and lists plan documents, charter and bylaw excerpts, legal opinions, auditor consent, and a filing fee table. The filing describes conversion of certain Amedisys RSU awards into Company restricted stock units using an equity award exchange ratio and references the Company’s fiscal year-end disclosure.
UnitedHealth Group reported second-quarter 2025 consolidated revenue of $111.6 billion, up 13% from $98.9 billion a year earlier, driven by premium growth (+14% to $87.9 billion), Optum Rx volume growth and pricing trends. Despite higher revenue, earnings from operations fell to $5.15 billion (down 35%) and net earnings were $3.57 billion (diluted EPS $3.74), reflecting elevated medical costs and Medicare Advantage funding pressures.
Medical costs rose 20% to $78.6 billion for the quarter, pushing the medical care ratio to 89.4% from 85.1%. Year-to-date results show net earnings of $10.05 billion and diluted EPS of $10.61, strong cash from operations of $12.6 billion for six months, available liquidity of about $77.3 billion in cash and investments, a June dividend increase to an $8.84 annual rate, $3.0 billion of senior notes issued in June, and approximately $4 billion of anticipated acquisition capital committed (subject to approvals).
FAQ
What is the current stock price of Unitedhealth Gp (UNH)?
What is the market cap of Unitedhealth Gp (UNH)?
